Boundless Bio, Inc. (BOLD)

Boundless Bio Statistics

Total Valuation

Boundless Bio has a market cap or net worth of $28.20 million. The enterprise value is -$39.61 million.

Market Cap	28.20M
Enterprise Value	-39.61M

Important Dates

The last earnings date was Wednesday, November 5, 2025, before market open.

Earnings Date	Nov 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Boundless Bio has 22.38 million shares outstanding. The number of shares has increased by 90.73% in one year.

Current Share Class	22.38M
Shares Outstanding	22.38M
Shares Change (YoY)	+90.73%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	1.72%
Owned by Institutions (%)	44.68%
Float	16.46M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.26
P/TBV Ratio	0.26
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 10.14, with a Debt / Equity ratio of 0.45.

Current Ratio	10.14
Quick Ratio	9.93
Debt / Equity	0.45
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -44.88% and return on invested capital (ROIC) is -26.08%.

Return on Equity (ROE)	-44.88%
Return on Assets (ROA)	-24.66%
Return on Invested Capital (ROIC)	-26.08%
Return on Capital Employed (ROCE)	-43.24%
Revenue Per Employee	n/a
Profits Per Employee	-$965,000
Employee Count	64
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -57.86% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-57.86%
50-Day Moving Average	1.26
200-Day Moving Average	1.42
Relative Strength Index (RSI)	41.73
Average Volume (20 Days)	145,339

Short Selling Information

The latest short interest is 99,719, so 0.45% of the outstanding shares have been sold short.

Short Interest	99,719
Short Previous Month	75,423
Short % of Shares Out	0.45%
Short % of Float	0.61%
Short Ratio (days to cover)	0.95

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-67.83M
Pretax Income	-61.76M
Net Income	-61.76M
EBITDA	-66.59M
EBIT	-67.83M
Earnings Per Share (EPS)	-$2.76

Balance Sheet

The company has $117.57 million in cash and $49.76 million in debt, giving a net cash position of $67.81 million or $3.03 per share.

Cash & Cash Equivalents	117.57M
Total Debt	49.76M
Net Cash	67.81M
Net Cash Per Share	$3.03
Equity (Book Value)	110.17M
Book Value Per Share	4.92
Working Capital	108.31M

Cash Flow

In the last 12 months, operating cash flow was -$52.12 million and capital expenditures -$588,000, giving a free cash flow of -$52.71 million.

Operating Cash Flow	-52.12M
Capital Expenditures	-588,000
Free Cash Flow	-52.71M
FCF Per Share	-$2.35

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Boundless Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-90.73%
Shareholder Yield	-90.73%
Earnings Yield	-218.98%
FCF Yield	-186.87%

Analyst Forecast

The average price target for Boundless Bio is $4.00, which is 217.46% higher than the current price. The consensus rating is "Buy".

Price Target	$4.00
Price Target Difference	217.46%
Analyst Consensus	Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1